April 6th 2024
Adam de Smith, PhD, discussed findings from a study investigating a genetic variant that increases the risk of acute lymphoblastic leukemia in Hispanic/Latino pediatric patients.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
A Little STING May Enhance the Immune System Against Cancer
April 25th 2015Despite their promise, checkpoint inhibitors are not effective in every patient, and research suggests the STING (stimulator of interferon genes) pathway may hold important clues as to why some tumors fail to respond.
Read More
Duvelisib Shows Encouraging Activity in Lymphoma
April 9th 2015Duvelisib (IPI-145) is an orally administered, dual inhibitor of phosphoinositide 3-kinase (PI3K) delta (δ) and gamma (γ) isoforms, and the drug is selective for PI3K class I isoforms over other lipid and protein kinases.
Read More
New Treatments for Hodgkin Lymphoma Coming to Clinics
March 17th 2015Although treatments and cure rates have increased significantly over the past 60 years for patients with HL, it is crucial that practitioners stay up-to-date on research that can affect outcomes for their patients with this uncommon form of cancer.
Read More
Ibrutinib Regimen Delays Disease Progression in Phase III CLL Trial
March 17th 2015Combination therapy with ibrutinib plus bendamustine and rituximab significantly extended progression-free survival compared with BR alone in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma enrolled in the phase III HELIOS trial.
Read More
Winter Hematology Meeting Highlighted by Talks on Immunotherapy, Personalized Medicine
February 21st 2015Experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.
Read More
BioT3 Integrates Diagnosis With Actionable Biomarkers in Metastatic Cancer
January 28th 2015Metastatic disease accounts for the vast majority of cancer-related deaths. Ensuring a definitive diagnosis and the most effective treatment in a timely fashion is essential for extending life expectancy.
Read More
Upfront Fulvestrant Improves OS Compared With Anastrozole in HR-Positive MBC
December 13th 2014Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer. These findings from the phase II FIRST trial were presented at the 2014 San Antonio Breast Cancer Symposium.
Read More
AG-221 Sparks Durable Remissions in IDH2-Mutated AML
December 8th 2014The novel drug AG-221 generated durable remissions in patients with acute myeloid leukemia (AML) by targeting a mutation of the IDH2 gene in a small, first-in-man study that represents a new, chemotherapy-free approach for attacking the malignancy. Eytan M. Stein, MD, reported these findings during a press briefing at the 56th Annual Meeting of the American Society of Hematology (ASH).
Read More